2025.07.31 16:39
SEOUL, South Korea — Cellid Co. (KOSDAQ: 299660), a South Korean biotechnology company, announced on July 29, 2025, that it has received a European patent for its proprietary adenovirus vector platform, used in its COVID-19 vaccine candidate AdCLD-CoV19-1 OMI.The patent covers an optimized vector structure designed for large-scale production of replication-incompetent adenoviruses. This achievement follows similar patent approvals in South Korea, the United States, China, Japan, and Russia, with applications still under review in Vietnam, Indonesia, Thailand, and Brazil. During the production
2025.07.31 16:36
SEOUL, South Korea — A research team led by Professors Byung-Chul Cho and Ki-Bbeum Lee, along with resident physician Ju-Seong Sim at the Yonsei Cancer Center, has identified new possibilities for MET gene-targeted therapy in solid tumor treatment, according to a study published on July 30 in Nature Reviews Clinical Oncology, a leading journal in the oncology field.The MET gene, which plays a key role in cancer cell proliferation and metastasis, has long been a primary target in the treatment of non-small cell lung cancer (NSCLC). MET overexpression in NSCLC has been associated with favorable
2025.07.31 16:33
BUSAN, South Korea — Samyook Busan Hospital announced on July 30 that it has been named one of Busan’s top institutions for international patient care in 2024 by the Busan Metropolitan City government, marking its second consecutive year receiving the honor.The recognition is part of Busan’s annual initiative to promote medical tourism, honoring 30 outstanding institutions, including general hospitals, clinics, and medical tourism agencies, based on their success in attracting foreign patients. Samyook Busan Hospital was listed among the top 10 general hospitals, alongside prominent institu
2025.07.31 16:30
SEOUL, South Korea — FirstBioTherapeutics, a biotechnology startup based in South Korea, announced on July 30 that it has been selected to join NVIDIA’s Inception program—a global initiative that supports startups leveraging artificial intelligence, data science, and high-performance computing.Through NVIDIA Inception program, selected companies gain access to GPU technologies, software development tools, technical training, and venture capital connections—aimed at accelerating innovation in frontier industries.FirstBioTherapeutics is applying AI technologies to improve the speed and accur
2025.07.31 16:28
CHICAGO — Boditech Med, a leading South Korean provider of point-of-care diagnostics, showcased a comprehensive portfolio of in-vitro diagnostic solutions at the Association for Diagnostics & Laboratory Medicine (ADLM) 2025 conference, held from July 29 to 31 in Chicago. The annual event, one of North America’s premier gatherings for laboratory medicine, attracted over 20,000 healthcare professionals and 800 companies, focusing on advancements in genomics-driven personalized diagnostics, environmental toxin detection, and artificial intelligence applications in healthcare.The company spotlig
2025.07.31 16:25
SEOUL, South Korea — Caregen, a South Korean biotech company specializing in peptide therapeutics, announced on July 30 that its weight-management peptide, Korglutide, has been officially approved as a health supplement by Indian health authorities.This regulatory milestone paves the way for Caregen to distribute and commercialize Korglutide in India, one of the world’s fastest-growing health and wellness markets. Korglutide, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, offers a competitive edge over injectable GLP-1 therapies by providing user convenience and helping to preserv
2025.07.31 16:22
SEOUL, South Korea — A research team at Seoul National University Hospital has achieved a significant breakthrough in diagnosing moyamoya disease—a rare pediatric cerebrovascular disorder—by identifying a novel blood-based biomarker. The microRNA marker, miR-512-3p, shows promise as a non-invasive diagnostic tool, potentially reducing reliance on high-risk procedures such as cerebral angiography.Moyamoya disease is a progressive condition marked by narrowing of the brain’s major arteries and the formation of abnormal collateral vessels. Predominantly affecting children, it can lead to seri
2025.07.31 16:15
SEOUL, South Korea — Dencom, a South Korean medical AI company, announced on July 30 that it has signed technology and supply agreements with three U.S.-based dental IT firms—Asprodental, Casenote Software, and Velmeni. These partnerships aim to introduce Dencom’s AI-powered voice solutions to the U.S. dental market, beginning with small and mid-sized clinics and scaling to Dental Service Organizations (DSOs) and larger healthcare systems. The company has set an ambitious U.S. revenue target of $7 million by next year. Dencom’s AI solution incorporates a lightweight language model (sLLM) a
2025.07.31 16:11
SEOUL, South Korea — Chung-Ang University Hyundai Hospital announced on July 29 that it had completed a nine-day medical mission in Kazakhstan, held from July 19 to 27, delivering essential healthcare services to local communities.The mission comprised 84 volunteers, including orthopedic surgeons, general surgeons, gastroenterologists, and cardiologists from Hyundai Hospital, along with medical personnel from Mongolia’s Hyundai Hospital and local Kazakh healthcare providers. Participants also included students from Chung-Ang University’s Colleges of Medicine and Nursing, nursing students fr
2025.07.31 16:08
TThe eyelids are often the first facial feature to show visible signs of aging. Their exceptionally thin skin and minimal subcutaneous fat make them especially prone to sagging from constant eye movement and gravity. AAs people reach middle age, the double eyelid line may become less defined or smaller, contributing to a heavy, fatigued appearance. This sagging can obstruct vision, cause eyelashes to turn inward, and lead to symptoms such as inflammation, irritation, or discomfort around the eyes.In addition to aesthetic concerns, these functional problems can affect quality of life, and a dro
2025.07.31 14:54
대전대학교 한방병원 연구팀이 한약제제 인진오령산이 대사성 지방간염(MASH) 개선에 효과가 있음을 밝혀냈다. 미국 QPS 연구소와의 국제 공동연구로 진행된 이번 연구는 ‘Journal of Ethnopharmacology’에 최근 발표됐다.연구팀은 서구화된 식습관으로 유도된 동물 모델과 인체 간세포 모델에 인진오령산을 투여해 간 지방 축적, 염증, 섬유화, 세포자멸사를 현저히 억제하는 효과를 확인했다. 간 효소(AST, ALT)와 중성지방, 콜레스테롤 수치도 정상 범위로 회복됐다.특히 이번 연구는 인진오령산이 YAP/TAZ 신호전달 경로를 억제해 간 섬유화와 종양 발생 관련 핵심 분자를 조절한다는 점을 처음으로 규명했다. 주요 성분인 알리솔 B, 시나믹
2025.07.31 14:48
여름철 무더위와 장마로 인해 다리 혈관이 부풀거나 튀어나오는 하지정맥류 환자가 늘고 있다. 하지정맥류는 다리 혈관 내 판막 기능이 약해지면서 혈액이 심장 대신 다리 쪽으로 역류해 혈관이 늘어나는 질환이다. 장시간 서 있거나 복부 비만, 무리한 운동 등이 주요 원인으로 꼽힌다.하지정맥류 초기에는 다리 혈관이 울퉁불퉁해지고 붓거나 통증, 피로감, 야간 경련 등의 증상이 나타난다. 시간이 지날수록 증상이 악화돼 심각한 합병증으로 이어질 수 있으므로, 초기 증상이 발견되면 지체 없이 의료기관을 찾아 정확한 검사를 받고 치료받는 것이 중요하다.전정욱 수원푸른맥외과 원장은 “하지정맥류는 단순 증상 완화가 아닌 근본 원인을
2025.07.31 13:59
의료·건강 전문 매체 헬스인뉴스(하이뉴스)가 주최한 ‘병원 홍보마케팅 전문가 과정’이 지난 26일 여의도에서 성공적으로 열렸다.이번 교육은 디지털 전환과 환자 중심 의료환경 변화에 발맞춰 병원의 지속 가능한 성장을 지원하고자 기획됐다. 소수 정예 실무 중심 교육으로, 병원 홍보마케팅 실무자부터 의료기관 경영진까지 다양한 직군의 참가자들이 한자리에 모였다.교육은 AI 기반 보도자료 및 칼럼 작성, 블로그·스마트플레이스 최적화 전략, 콘텐츠 기획 및 카드뉴스 제작 실습, 네이버 공식블로그 운영 및 인플루언서 협업 전략, 위기관리 및 평판 관리 등 실무와 전략을 아우르는 커리큘럼으로 구성됐다.특히, AI를 활용한 콘텐츠
주소: (07327) 서울특별시 영등포구 국제금융로2길 17 시티플라자 421호 | 전화: 02-313-2382 | 이메일: press@hinews.co.kr
제호: hinews(하이뉴스) | 등록번호: 서울,아04641 | 발행일: 2017. 8. 4
대표이사: 김국주 | 발행인: 굿닥터홀딩스 주식회사 김국주 | 편집인: 이상호 | 청소년보호책임자: 임혜정
Hinews의 모든 콘텐츠는 저작권법의 보호를 받으며 무단전재, 복사, 배포를 금합니다.
Copyright ⓒHinews. All rights reserved.
